Predictive Factors Affecting Metastasis of Small Renal Mass and Its Prognostic Analysis

Wei He*, Zhuo Liu*, Yu Tian*, Yuxuan Li, Chuxiao Xu, Ruotao Xiao, Peng Hong, Shiying Tang, Liyuan Ge, Xun Zhao, Guodong Zhu, Hongxian Zhang, Cheng Liu and Lulin Ma

Department of Urology, Peking University Third Hospital, Beijing, China.

ABSTRACT

BACKGROUND: The incidence of small renal mass (SRM) increases, and the prognosis of SRM is poor once metastasized. Therefore, we conducted this study to assess the clinical and pathological characteristics of SRM to determine the risk factors that influence the metastasis and prognosis of SRM.

METHODS: A small renal mass is defined as a solid tumor mass with the largest diameter of 4 cm or less on the pathological diagnosis. The metastasis is confirmed by imaging or pathological examination. We retrospectively included 40 patients with metastatic SRM (mSRM) treated in the department of urology of Peking University Third Hospital from October 2002 to October 2020. Meanwhile, 358 patients with nonmetastatic SRM treated in our hospital from January 2015 to December 2017 were selected as controls. Clinicopathologic features were compiled.

RESULTS: Multivariate logistic regression analysis showed that age (P = .027, odds ratio [OR] = 1.037, 95% confidence interval [CI] 1.004-1.070), clinical symptoms (P < .001, OR = 4.311, 95% CI 1.922-9.672), World Health Organization/International Society of Urological Pathology (WHO/ISUP) nuclear grade 3/4 (P = .004, OR = 7.637, 95% CI 1.943-30.012; P = .004, OR = 20.523, 95% CI 2.628-160.287), and lymphatic invasion (P = .030, OR = 15.844, 95% CI 1.314-191.033) were risk factors for distant metastasis of SRM. Once metastasis occurs, the prognosis of SRM is poor. Multivariate Cox regression analysis of the prognosis of mSRM showed that age (P = .016, hazard ratio [HR] = 1.125, 95% CI 1.022-1.239), preoperative serum creatinine (P = .041, HR = 1.003, 95% CI 1.000-1.005), vascular invasion (P = .041, HR = 1.003, 95% CI 1.000-1.005), and metastasis (P < .001, HR = 24.069, 95% CI 4.549-127.356) were risk factors for overall survival (OS), and only metastasis (P < .001, HR = 9.52, 95% CI 5.43-16.7) was a risk factor for progression-free survival (PFS) of SRM.

CONCLUSIONS: SRM with advanced age, clinical symptoms, high pathological nuclear grade, and lymphatic invasion are more likely to have distant metastasis. And SRM with older age, poor preoperative basic renal function, pathological vascular invasion, and metastasis have worse OS.

KEYWORDS: Renal cell carcinoma, small renal mass, metastasis, predictive factor, prognosis

RECEIVED: July 25, 2021. ACCEPTED: January 4, 2022.
TYPE: Original Research Article
FUNDING: The author(s) received no financial support for the research, authorship, and/or publication of this article.

DECLARATION OF CONFLICTING INTERESTS: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
CORRESPONDING AUTHOR: Lulin Ma, Department of Urology, Peking University Third Hospital, No. 49 North Garden Road, Haidian District, Beijing 100191, China. Email: malulin@medmail.com.cn

Introduction

Renal cancer is a common malignant tumor of the urinary system, with approximately 76,000 new cases in the United States every year, accounting for about 4% of all cancer types.1 A small renal mass (SRM) is defined as a solid tumor mass with the largest diameter of 4 cm or less on the pathological diagnosis.2 At present, the increase in SRM detection is associated with ultrasound and other screening technologies.3 Robot-assisted or laparoscopic partial nephrectomy is an accepted standard of care for SRM. For patients with renal sinus invasion, renal pelvis invasion, or renal vein cancer embolism, robot-assisted or laparoscopic radical nephrectomy is usually adopted.4

However, about 2% to 7% of SRM will metastasize.5-8 Patients with mSRM are treated with systemic therapies, including tyrosine kinase inhibitor (TKI)-targeted therapies or immunotherapies.4 The prognosis is generally poor in those patients. The 5-year specific survival rate is approximately 10%, and the median overall survival (OS) is 10 to 15 months.9 However, research on the clinicopathological characteristics and prognosis of mSRM is limited. Therefore, we conducted this study to assess the clinical and pathological characteristics of SRM to determine the risk factors that influence the metastasis and prognosis of SRM.

Population and Methods

Patients

We retrospectively included 40 patients with mSRM treated in the department of urology of Peking University Third Hospital from October 2002 to October 2020. Meanwhile, 358 patients with nonmetastatic SRM treated in our hospital from January 2015 to December 2017 were selected as controls.

All included patients met the following inclusion criteria: (1) with histologically confirmed renal cell carcinoma, (2) maximum tumor diameter of 4 cm or less. Metastasis can be examined during initial diagnosis or follow-up. Different examinations were used to confirm potential metastases at specific sites: lung metastasis usually was identified by chest
computerized tomography (CT); liver metastasis and adrenal metastasis used abdominal ultrasound or abdominal CT; bone scan was received if there was an abnormal increase of alkaline phosphatase or symptoms of bone metastasis such as bone pain; patients with signs of the acute nervous system would receive immediate CT or magnetic resonance image (MRI) scan on the head or spinal cord based on the corresponding segmental symptoms; for patients with good economic conditions or systemic symptoms, positron emission tomography–computed tomography (PET-CT) was performed; pathological examination would be selected when necessary.

For this study, demographic characteristics (age, gender, height, weight, body mass index [BMI]) of each patient and whether there was any clinical symptom (including systemic symptoms such as fever, fatigue, weight loss, cachexia, and local symptom such as pain, local mass, hematuria) were collected. The operative time and intraoperative blood loss were used to represent the difficulty of operation, and the American Society of Anesthesiologists (ASA) score was used to evaluate the risk of anesthesia and operation. Detailed histologic characteristics, including pathologic type, tumor diameter, World Health Organization/International Society of Urological Pathology (WHO/ISUP) nuclear grade, invasion of renal sinus, vascular invasion, lymphatic invasion, presence of sarcomatoid component or rhabdoid component, were also recorded.

Outpatient check-ups and telephone interviews strictly followed up patients after surgery. The follow-up evaluation comprised physical examination, renal function, and abdominal ultrasound performed every 3 to 6 months for the first 2 years after surgery, every 6 to 12 months from postoperative 3 to 5 years, and every 12 months after that.

**Statistical Methods**

Progression-free survival (PFS) is defined as the time from diagnosis to first disease progression or death from any cause; OS is defined as the time from diagnosis to death from any cause.

SPSS IBM 18.0 software was used for analysis. Normal distribution was tested with the Kolmogorov-Smirnov test for continuous variables. For the normal distribution, the mean ± standard deviation was used. The clinical and pathological features of patients with and without metastases were analyzed using two independent samples t test. For nonnormal distribution data, the median with the interquartile range was used to represent, and nonparametric tests were used to compare the differences between the two groups of distributions. The classification data were represented by frequency (percentage), and the chi-square test compared the difference of proportion between groups. Those who did not meet the chi-square test were compared by Fisher’s exact probability method. P < .05 was considered statistically significant. Multivariate logistic regression analysis was used to identify risk factors for metastasis of SRM. Univariate and multivariate Cox proportional hazards analyses were applied in the analysis of OS and PFS. Variables achieving P < .05 in the univariate analysis were incorporated in the multivariate model to determine independent prognostic factors.

**Results**

A total of 398 patients were retrospectively collected from October 2002 to October 2020 by searching electronic medical records. Forty patients in the group of mSRM, and 358 patients with nonmetastatic SRM were included in the control group. The clinical and pathological data of the patients were shown in Tables 1 and 2. Univariate analysis of the clinical and pathological features between the two groups showed that there were significant differences in age (P = .002), clinical symptoms (P < .001), operation approach (P < .001), operative time (P = .033), intraoperative blood loss (P = .001), ASA score (P = .008), tumor diameter (P = .016), WHO/ISUP nuclear grade (P < .001), lymphatic invasion (P < .001), and perirenal fat invasion (P = .009). Multivariate logistic regression analysis showed that age (P = .027, odds ratio [OR] = 1.037, 95% confidence interval [CI] 1.004-1.070), clinical symptoms (P < .001, OR = 4.311, 95% CI 1.922-9.672), WHO/ISUP nuclear grade (P = .004, OR = 7.637, 95% CI 1.943-30.012; P = .004, OR = 20.523, 95% CI 2.628-160.287), and lymphatic invasion (P = .030, OR = 15.844, 95% CI 1.314-191.033) were risk factors for distant metastasis of SRM (Table 3).

Among the 40 patients with metastatic SRM, 16 cases had metastasis at initial diagnosis, and 24 cases had metastasis during follow-up. Lung metastasis was found in 14 cases (35%), bone metastasis in 10 cases (25%), adrenal metastasis in 4 cases (10%), other site metastasis in 4 cases (10%), and 8 cases (20%) had metastasized in more than 2 metastatic sites. A total of 50 metastatic lesions were found in 40 patients, including 17 (34%) pulmonary metastases, 16 (32%) bone metastases, 2 (4%) liver metastases, 1 (2%) brain metastases, 7 (14%) adrenal metastases, and 7 (14%) other metastases (Figure 1).

Multivariate Cox regression analysis of the prognosis of SRM showed that age (P = .016, hazard ratio [HR] = 1.125, 95% CI 1.022-1.239), preoperative serum creatinine (SCR; P = .041, HR = 1.003, 95% CI 1.000-1.005), vascular invasion (P = .041, HR = 1.003, 95% CI 1.000-1.005), and metastasis (P < .001, HR = 24.069, 95% CI 4.549-127.356) were risk factors for OS (Table 4), and only metastasis (P < .001, HR = 9.52, 95% CI 5.43-16.7) was a risk factor for PFS of SRM (Table 5).

In our study, the median follow-up time was 38 months, and the median survivorship time was not achieved because of the short follow-up period. The OS rate (P = .002, HR = 14.128, 95% CI 2.698-73.967 & P < .001, HR = 19.721, 95% CI 6.296-61.767) and PFS rate (P < .001, HR = 20.22, 95% CI 7.205-56.75) of mSRM were significantly shortened; meanwhile, there was no statistical difference between the prognosis of patients with synchronous metastasis and that of patients with metachronous metastasis (P = .762) (shown in Figures 2 and 3).
Discussion

With the popularity of ultrasound, CT, and other imaging examinations, the incidence of SRM is gradually increasing. For SRM, the guidelines recommend that a biopsy be performed before treatment. Of all surgically resected SRM, approximately 25% are benign, and the other 25% are indolent tumors with limited metastatic potential. Generally, we believe that the larger the tumor size, the higher the risk of metastasis. Some studies have shown that the progression of SRM is slow and the risk of metastasis is low; active monitoring surgery is an option for elderly patients and patients with more complications that are not suitable for surgery. However, about 2% to 7% of SRM with metastasis. For SRM with metastasis at initial diagnosis, or patients with metastasis during follow-up, the treatment is based on metastatic renal cell carcinoma guidelines, and the prognosis is poor.

Our study found that mSRM was easier to choose open surgery and radical nephrectomy; we considered that there were more malignant manifestations found in the preoperative imaging evaluation, such as suspected invasion of the renal pelvis and calyx, or the presence of cystic components that may lead to local implantation, as well as intraoperative reasons.

Besides, longer operation time and more intraoperative blood loss suggest that the operation is more difficult. The existing literature shows that patients with metastatic renal cell carcinoma (mRCC) can still benefit from cytoreductive surgery than patients with systemic therapy alone, and patients who undergo cytoreductive surgery after systemic treatment also show benefits in OS time and time to treatment failure. Under the premise of immunotherapy, cytoreductive surgery can also benefit patients. All of the patients we included have undergone surgery, so they cannot be compared with patients who have received systemic treatment alone. Moreover, patients with mSRM may be older and have obvious clinical manifestations because of treatment-seeking delay. At present, few studies are predicting the metastatic risk of SRM. Zastrow et al analyzed 2058 cases of RCC and found that tumor size and ASA score were important prognostic factors of synchronous metastasis. Takayama et al studied 451 cases of T1a RCC, of which 32 cases were associated with metastasis. They reported that symptoms at diagnosis, CRP ≥ 0.4 mg/dL, tumor size ≥ 3.0 cm, histological grade 3, sarcomatoid component, and microvascular invasion were independent risk factors for metastasis. Another study has found that diabetes mellitus is

|   | METASTASIS (N=40) | NONMETASTASIS (N=358) | P   |
|---|-----------------|------------------------|-----|
| Gender | Male 31 (77.5%) 258 (72.1%) | Female 9 (22.5%) 100 (27.9%) | .465 |
| Age | 63 (54.25, 67.75) 55 (47, 63) | .002 |
| BMI | 24.89 (22.35, 28.55) 25.19 (23.18, 27.09) | .441 |
| Clinical symptoms | Absence 23 (57.5%) 303 (84.6%) | Presence 17 (42.5%) 55 (15.4%) | <.001 |
| Hypertension | No 22 (55%) 230 (64.2%) | Yes 18 (45%) 128 (35.8%) | .25 |
| Diabetes mellitus | No 31 (77.5%) 296 (82.7%) | Yes 9 (22.5%) 62 (17.3%) | .417 |
| Cardiovascular disease | No 36 (90%) 325 (90.8%) | Yes 4 (10%) 33 (9.2%) | 1 |
| ASA score | 1 3 (7.5%) 90 (25.1%) | 2 33 (82.5%) 253 (70.7%) | .008 |
| 3 | 4 (10%) 14 (3.9%) | 4 0 (0%) 1 (0.3%) |
| Preoperative serum creatinine | 80.5 (70, 93) 83 (72, 96) | .319 |

Abbreviations: ASA, American Society of Anesthesiologists; BMI, body mass index; SRM, small renal mass.
Table 2. Comparison of intraoperative and postoperative features between all SRM and those associated with distant metastatic disease.

| Feature                                      | METASTASiS (N=40) | NONMETASTASiS (N=358) | P     |
|----------------------------------------------|-------------------|-----------------------|-------|
| Surgical approach                            |                   |                       |       |
| Retroperitoneal laparoscopic surgery          | 32 (80%)          | 195 (54.5%)           | <.001 |
| Transperitoneal laparoscopic surgery          | 6 (15%)           | 163 (45.5%)           |       |
| Open surgery                                 | 2 (5%)            | 0 (0%)                |       |
| Partial nephrectomy (PN)                     | 15 (37.5%)        | 306 (85.5%)           | <.001 |
| Radical nephrectomy (RN)                     | 25 (62.5%)        | 52 (14.5%)            |       |
| Tumor side                                   |                   |                       | .301  |
| Left                                         | 23 (57.5%)        | 175 (48.9%)           |       |
| Right                                        | 17 (42.5%)        | 183 (51.1%)           |       |
| Operative time (min)                         | 168.5 (128.5, 215.75) | 145 (119.75, 183) | .033  |
| Intraoperative blood loss                    | 50 (20, 100)      | 20 (10, 50)           | .001  |
| Postoperative complications                  |                   |                       | .413  |
| No                                           | 39 (97.5%)        | 354 (98.9%)           |       |
| Yes                                          | 1 (2.5%)          | 4 (1.1%)              |       |
| Tumor diameter (cm)                          | 3 (2.8, 3.5)      | 2.8 (2.1, 3.4)        | .016  |
| Pathological type                            |                   |                       | .498  |
| Clear cell                                   | 37 (92.5%)        | 313 (87.4%)           |       |
| Nonclear cell                                | 3 (7.5%)          | 45 (12.6%)            |       |
| WHO/iSUP nuclear grade                       | (n=37)            | (n=335)               | <.001 |
| 1                                            | 3 (8.1%)          | 63 (18.8%)            |       |
| 2                                            | 15 (40.5%)        | 231 (69%)             |       |
| 3                                            | 15 (40.5%)        | 38 (11.3%)            |       |
| 4                                            | 4 (10.8%)         | 3 (0.9%)              |       |
| Lymphatic invasion                           |                   |                       | <.001 |
| No                                           | 36 (90%)          | 357 (99.7%)           |       |
| Yes                                          | 4 (10%)           | 1 (0.3%)              |       |
| Renal sinus invasion                         |                   |                       | .051  |
| No                                           | 34 (85%)          | 338 (94.4%)           |       |
| Yes                                          | 6 (15%)           | 20 (5.6%)             |       |
| Perirenal fat invasion                       |                   |                       | .009  |
| No                                           | 35 (87.5%)        | 348 (97.2%)           |       |
| Yes                                          | 5 (12.5%)         | 10 (2.8%)             |       |
| Vascular invasion                            |                   |                       | .187  |
| No                                           | 38 (95%)          | 352 (98.3%)           |       |
| Yes                                          | 2 (5%)            | 6 (1.7%)              |       |
| Necrosis                                     |                   |                       | .294  |
| No                                           | 40 (100%)         | 340 (95%)             |       |
| Yes                                          | 0 (0%)            | 18 (5%)               |       |
| Renal venous tumor thrombus                  |                   |                       | .346  |
| No                                           | 39 (97.5%)        | 355 (99.2%)           |       |
| Yes                                          | 1 (2.5%)          | 3 (0.8%)              |       |
| Sarcomatoid component                        |                   |                       | .101  |
| No                                           | 39 (97.5%)        | 358 (100%)            |       |
| Yes                                          | 1 (2.5%)          | 0 (0%)                |       |
| Rhabdomyoid component                        |                   |                       | 1     |
| No                                           | 40 (100%)         | 358 (100%)            |       |
| Yes                                          | 0 (0%)            | 0 (0%)                |       |

Abbreviations: SRM, small renal mass; WHO/iSUP, World Health Organization/International Society of Urological Pathology.
an independent predictor of metastasis in T1a RCC patients.\textsuperscript{20} Tan et al found that age, tumor size, symptoms, and ipsilateral synchronous tumors were independent risk factors for predicting metastasis.\textsuperscript{21} Several works of the literature suggest that tumor size is a risk factor for metastasis. Tumor size has a statistical difference in the univariate analysis of our results, but it loses significance after multivariate analysis, which may be due to the greater weighting of other factors. In addition, high nuclear grade and lymphatic invasion are risk factors for metastasis, while in Tan’s study, they are independent predictors for disease recurrence.\textsuperscript{21}

At present, limited by the number of cases, few studies are still on the prognosis of metastatic SRM. As early as 2001, Yaycioglu et al developed a prognostic model using only preoperative clinical variables after analyzing 296 cases of open radical nephrectomy.\textsuperscript{22} Kattan summarized the data of 601 cases of nephrectomy and constructed a nomogram, including histological type, tumor size, Tumor-node-metastasis (TNM) classification, and clinical manifestations, to evaluate the possibility of recurrence after a 5-year follow-up.\textsuperscript{23} In 2002, Igor et al proposed a system (the tumor stage, size, grade and necrosis [SSIGN] score) based on tumor staging, size, nuclear grade, and histological tumor necrosis.\textsuperscript{24} Memorial Sloan-Kettering Cancer Center (MSKCC) score, developed by Motzer et al, is one of the most widely used predictive models for mRCC patients. Patients are divided into three risk groups (good, moderate, and poor) according to the number of adverse factors (for example, less than 1 year from diagnosis to initiation of systemic treatment, corrected elevated serum calcium, elevated lactate dehydrogenase [LDH], low hemoglobin levels and low Karnofsky PS score).\textsuperscript{25} Another well-known University of California Los Angeles Integrated Staging System (UISS) scoring system for RCC combined TNM classification, Eastern Cooperative Oncology Group (ECOG) PS score, and the Fuhrman score. In this system, patients are divided into 3 categories (low, medium, and high risk) to predict OS.\textsuperscript{26} Kume et al retrospectively analyzed the surgical treatment of 165 cases with SRM \( \leq 3 \) cm, and concluded that microvascular infiltration was an important prognostic factor for patients with a less than 3 cm tumor.\textsuperscript{27} Although we did not form a predictive model because of the limited number of cases, we also found the risk factors affecting the PFS and OS of SRM. Judging from our result, patients with metastasis were more likely to progress, while patients with older age, poor preoperative basic renal function, pathological vascular invasion, and metastasis had worse overall prognoses.

The 5-year OS rate of localized RCC can reach 92.7\%, but it will directly drop to 13.9\% once metastasis occurs.\textsuperscript{28} The 5-year cancer-specific survivorship after nephrectomy of stage I renal cell carcinoma can reach 97.1\% to 98.1\%.\textsuperscript{29} For SRM, current studies have shown that the 5-year OS rate can reach 92\%, and the 5-year tumor-specific mortality rate is about 5.3\%,\textsuperscript{30,31} The median survival time of mSRM is about 37 to 38 months.\textsuperscript{32} In this result, we can also see a significant decrease in the OS of mSRM. A meta-analysis found that the local progression rate after localized partial nephrectomy was about 0.4\%.\textsuperscript{33} Our data found that the tumor PFS of mSRM was significantly shortened, and the median PFS was about 20 months. The literature reported that the longer the interval between initial diagnosis and metastasis, the better the prognosis.\textsuperscript{34} When we reviewed

### Table 3. Multivariate logistic regression analysis of metastatic risk factors for patients with SRM.

|                  | \( P \)  | OR (95% CI)       |
|------------------|---------|-------------------|
| Age              | .027    | 1.037 (1.004-1.070) |
| Clinical Symptoms| <.001   | 4.311 (1.922-9.672) |
| ASA score        | 2.0.485 |                   |
|                  | 3.0.519 |                   |
|                  | 4.0.815 |                   |
| Tumor diameter   | 0.075   |                   |
| WHO/ISUP Nuclear grade | 2.0.593 |                   |
|                  | 3.0.004 | 7.637 (1.943-30.012) |
|                  | 4.0.004 | 20.523 (2.628-160.287) |
| Lymphatic invasion| .030    | 15.844 (1.314-191.033) |
| Perirenal fat invasion| .256 |                   |

Abbreviations: ASA, American Society of Anesthesiologists; CI, confidence interval; OR, odds ratio; WHO/ISUP, World Health Organization/International Society of Urological Pathology.
Clinical Medicine Insights: Oncology

all mRCC patients in our center, we found that the survival of synchronous metastatic patients was worse than that of metachronous metastatic patients. However, no statistical difference was found in patients with SRM which may be due to the small number of samples.

The present study has several limitations:

1. The main limitation of the present study is the relatively short follow-up time that may underestimate the potential of metastasis of nonmetastatic SRM, and potentially affect the outcome of the study. Although the median follow-up lasted more than 36 months, longer follow-up is required to validate the current findings.
2. The metastasis of some cases depends on imaging diagnosis and has no pathological basis.
3. The definition of SRM depends on the maximum diameter of the pathological specimen, but it may be smaller than the actual size because of the fixation and sampling of the specimen.

Table 4. Univariate and multivariate regression analysis of prognostic risk factors (overall survival) for patients with SRM.

| Risk Factor                        | UNIVARIATE ANALYSIS                      | MULTIVARIATE ANALYSIS                      |
|------------------------------------|------------------------------------------|-------------------------------------------|
|                                   | HR (95% CI)                              | HR (95% CI)                               |
| Metastasis                         | 18.143(6.063-54.295)                     | 24.069 (4.549-127.356)                    |
| Age                                | 1.114(1.056-1.176)                       | 1.125 (1.022-1.239)                       |
| Preoperative SCR                   | 1.003(1.001-1.004)                       | 1.003 (1.000-1.005)                       |
| ASA score                          | 3.194 (0.391-26.096)                     | 0.785 (0.070-8.785)                       |
|                                   | 38.531(4.244-349.817)                    | 3.852 (0.241-61.532)                      |
|                                   | 97.398 (5.787-1639.410)                  | 8.590 (0.184-401.487)                     |
| PN/RN                              | 16.476(4.616-58.799)                     | 0.992 (0.180-5.470)                       |
| Postoperative complications        | 17.843(3.972-80.160)                     | 0.356 (0.000-2.055)                       |
| Vascular invasion                  | 20.721 (5.751-74.662)                    | 18.155 (3.565-92.458)                     |
| Renal venous tumor thrombus        | 27.472 (6.068-124.373)                   | 5.281 (0.000-3.070)                       |

Abbreviations: ASA, American Society of Anesthesiologists; CI, confidence interval; HR, hazard ratio; PN, partial nephrectomy; RN, radical nephrectomy; SCR, serum creatinine; SRM, small renal mass.

Table 5. Univariate and multivariate regression analysis of prognostic risk factors (progression-free survival) for patients with SRM.

| Risk Factor                        | UNIVARIATE ANALYSIS                      | MULTIVARIATE ANALYSIS                      |
|------------------------------------|------------------------------------------|-------------------------------------------|
|                                   | HR (95% CI)                              | HR (95% CI)                               |
| Metastasis                         | 8.28 (5.35-12.8)                         | 9.52 (5.43-16.7)                          |
| Gender                             | 1.06 (1.03-1.09)                         | 1.02 (0.99-1.06)                          |
| ASA score                          | 2.31 (1.16-4.58)                         | 2.05 (0.79-5.32)                          |
| RN/PN                              | 4.33 (2.04-9.2)                          | 0.81 (0.28-2.34)                          |
| Operative time                     | 1.01 (1-1.01)                            | 1.01 (1-1.02)                             |
| Intraoperative blood loss          | 1 (1-1)                                  | 1 (0.99-1)                                |
| WHO/ISUP nuclear grade             | 3.76 (2.24-6.32)                         | 1.43 (0.8-2.56)                           |
| Lymphatic invasion                 | 14.45 (1.94-107.53)                      | 0.28 (0.02-3.49)                          |
| Vascular invasion                  | 8 (1.87-34.14)                           | 1.62 (0.14-18.5)                          |
| Renal venous tumor thrombus        | 8.88 (1.17-67.58)                        | 7.63 (0.47006.22)                         |

Abbreviations: ASA, American Society of Anesthesiologists; CI, confidence interval; HR, hazard ratio; PN, partial nephrectomy; RN, radical nephrectomy; SRM, small renal mass; WHO/ISUP, World Health Organization/International Society of Urological Pathology.
Statement of Ethics

The study was approved by the Peking University Third Hospital Medical Science Research Ethics Committee. All of the procedures were performed in accordance with the Declaration of Helsinki and relevant policies in China (IRB:00006761-M2021003).

ORCID iD
Wei He https://orcid.org/0000-0002-9100-5581

REFERENCES

1. Siegel RL, Miller KD, Fuchs HE. Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71:7-33. doi:10.3322/caac.21654.
2. Gill JS, Aron M, Gervais DA, Jewett MAS. Clinical practice. Small renal mass. N Engl J Med. 2010;362:624-634. doi:10.1056/NEJMep0910041.
3. Ficarra V, Prayé-Galetti T, Novella G, et al. Incidental detection beyond pathological factors as prognostic predictor of renal cell carcinoma. Eur Urol. 2003;43:663-669.
4. Motzer RJ, Jonasch E, Boyle S, et al. NCCN guidelines insights: kidney cancer, version 1.2021. J Natl Compr Canc Netw. 2020;18:1160-1170. doi:10.6004/jnccn.2020.0043.
5. Umbricht EC, Shimko MS, Childs MA, et al. Metastatic potential of a renal mass according to original tumour size at presentation. BJU Int. 2012;109:190-194; discussion 194. doi:10.1111/j.1440-1673.2011.10184.x.
6. Gubnitssson E, Hellborg H, Lundstrom S, Erikson S, Ljungberg B. Metastatic potential in renal cell carcinomas ≤7 cm: Swedish Kidney Cancer Registry data. Eur Urol. 2011;60:975-982. doi:10.1016/j.eururo.2011.06.029.
7. Klarte T, Petrad J-J, De Martino M, et al. Tumor size does not predict risk of metastatic disease or prognosis of small renal cell carcinomas. J Urol. 2008;179:1719-1726. doi:10.1016/j.juro.2008.01.018.
8. Lughezzani G, Jeldres C, Isbarn H, et al. Tumor size is a determinant of the rate of stage T1 renal cell cancer synchronous metastasis. J Urol. 2009;182:1287-1293. doi:10.1016/j.juro.2009.06.018.
9. Choueiri TK, Motzer RJ. Systemic therapy for metastatic renal-cell carcinoma. N Engl J Med. 2017;376:354-366. doi:10.1056/NEJMe1601333.
10. Kane CJ, Mallin K, Ritchey J, Cooperberg MR, Carroll PR. Renal cell cancer stage migration: analysis of the National Cancer Data Base. Cancer. 2008;113:78-83. doi:10.1002/cncr.23518.
11. Finelli A, Ismaila N, Russo P. Management of small renal masses: American Society of Clinical Oncology clinical practice guideline summary. J Oncol Pract. 2017;13:276-278. doi:10.1200/JOP.2016.019620.
12. Daugherty M, Sedaghatpour D, Shapiro O, Vousganti S, Kurikov A, Bratslavsky G. The metastatic potential of renal tumors: influence of histologic subtypes on definition of small renal masses, risk stratification, and future active surveillance protocols. Urol Oncol. 2017;35:153.e15-153.e20. doi:10.1016/j.urolonc.2016.11.009.
13. Marra G, Oderda M, Allasia M, Municato S, Joniau S, Goenster P. A review on the management of small renal masses: active surveillance versus surgery. Anticancer Agents Med Chem. 2018;18:940-950. doi:10.2174/187152061766617111231443.
14. Liaw CW, Winkoer JS, Mehrzad R. Imaging protocols for active surveillance in renal cell carcinoma. Curr Urol Rep. 2018;19:81. doi:10.1007/s11934-018-0830-z.
15. Heng DY, Wells JC, Rini BI, et al. Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur Urol. 2014;66:704-710. doi:10.1016/j.eururo.2014.05.034.
16. Bhindi B, Graham J, Wells JC, et al. Deferred cytoreductive nephrectomy in patients with newly diagnosed metastatic renal cell carcinoma. Eur Urol. 2020;78:615-623. doi:10.1016/j.eururo.2020.04.038.
17. Stellato M, Santini D, Verzoni E, et al. Impact of previous nephrectomy on clinical outcome of metastatic renal carcinoma treated with immune-oncology: a real-world study on behalf of meet-URO group (MeetUro-7b). Front Oncol. 2021;11:682449. doi:10.3389/fonc.2021.682449.
18. Zastrow S, Phuong A, Von Bar I, Novotny V, Hakenberg OW, Wirth MP. Primary tumor size in renal cell cancer in relation to the occurrence of synchronous metastatic disease. Urol Int. 2014;92:462-467. doi:10.3389/fonc.2021.682449.
19. Takayama T, Sugiyama T, Kai F, et al. Characteristics of aggressive variants in T1a renal cell carcinoma. J Cancer Res Clin Oncol. 2011;137:1653-1659. doi:10.1007/s00432-011-1040-y.

20. Lee H, Lee JK, Kim K, et al. Risk of metastasis for T1a renal cell carcinoma. World J Urol. 2016;34:553-559. doi:10.1007/s00345-015-1659-4.

21. Tan YG, Khalid MFB, Villanueva A, Huang HH, Chen K, Sim ASP. Are small renal masses all the same? Int J Urol. 2020;27:439-447. doi:10.1111/iju.14219.

22. Yaycioglu O, Roberts WW, Chan T, Epstein JJ, Marshall FF, Kavoussi LR. Prognostic assessment of nonmetastatic renal cell carcinoma: a clinically based model. Urology. 2001;58:141-145.

23. Kattan MW, Reuter V, Motzer RJ, Katz J, Russo P. A postoperative prognostic nomogram for renal cell carcinoma. J Urol. 2001;166:63-67.

24. Frank I, Blute ML, Cheville JC, Lohse CM, Weaver AL, Zincke H. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J Urol. 2002;168:2395-2400.

25. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol. 2002;20:289-296.

26. Zisman A, Pantuck AJ, Dorey F, et al. Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol. 2001;19:1649-1657.

27. Kume H, Suzuki M, Fujimura T, et al. Distant metastasis of renal cell carcinoma with a diameter of 3 cm or less—which is aggressive cancer? J Urol. 2010;184:64-68. doi:10.1016/j.juro.2010.03.019.

28. Surveillance, Epidemiology, and End Results Program. SEER stat fact sheets: kidney and renal pelvis cancer. Bethesda, MD: National Cancer Institute. https://seer.cancer.gov/statfacts/html/kidrp.html

29. Cheaib JG, Patel HD, Johnson MH, et al. Stage-specific conditional survival in renal cell carcinoma after nephrectomy. Urol Oncol. 2020;38:e6. doi:10.1016/j.urolonc.2019.08.011.

30. Pierrozio PM, Johnson MH, Ball MW, et al. Five-year analysis of a multi-institutional prospective clinical trial of delayed intervention and surveillance for small renal masses: the DESSRM registry. Eur Urol. 2015;68:408-415. doi:10.1016/j.eururo.2015.02.001.

31. Hollingsworth JM, Miller DC, Daignault S, Hollenbeck BK. Five-year survival after surgical treatment for kidney cancer: a population-based competing risk analysis. Cancer. 2007;109:1763-1768.

32. DiNatale RG, Xie W, Bicerra MF, et al. The association between small primary tumor size and prognosis in metastatic renal cell carcinoma: insights from two independent cohorts of patients who underwent cytoreductive nephrectomy. Eur Urol Oncol. 2020;3:47-56. doi:10.1016/j.euo.2019.10.002.

33. Klatte T, Shariat SF, Renzi M. Systematic review and meta-analysis of perioperative and oncologic outcomes of laparoscopic cryoablation versus laparoscopic partial nephrectomy for the treatment of small renal tumors. J Urol. 2014;191:1209-1217. doi:10.1016/j.juro.2013.11.006.

34. Donkov F, Xie W, Overby A, et al. Synchronous versus metachronous metastatic disease: impact of time to metastasis on patient outcome—results from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur Urol Oncol. 2020;3:530-539. doi:10.1016/j.euo.2020.01.001.